Active CAR T-Cell Clinical Trials and Research Studies
The following are the active clinical trials currently available or anticipated in the Center for Adoptive Cellular Therapy.
Open CAR T-cell Clinical Trials
AALL1721 (CASSIOPEIA): A Phase 2 Trial of tisagenlecleucel in first-line high-risk pediatric and young adult patients with B-ALL who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy. This trial is sponsored by Novartis.
- ClinicalTrials.gov Identifier: NCT03876769. Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients - Full Text View - ClinicalTrials.gov
Upcoming CAR T-cell Clinical Trials
JCAR017 BCM004: A Phase 1/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL. This trial is sponsored by Bristol-Myers Squibb